Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $2.9 million.

  • Aclaris Therapeutics' Share-based Compensation fell 4.79% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 33.00%. This contributed to the annual value of $10.9 million for FY2024, which is 47.15% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Share-based Compensation stood at $2.9 million, which was down 6.63% from $3.1 million recorded in Q2 2025.
  • Aclaris Therapeutics' Share-based Compensation's 5-year high stood at $6.8 million during Q1 2023, with a 5-year trough of $1.3 million in Q4 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $3.0 million (2024), whereas its average is $3.7 million.
  • The largest annual percentage gain for Aclaris Therapeutics' Share-based Compensation in the last 5 years was 190.11% (2023), contrasted with its biggest fall of 73.70% (2023).
  • Aclaris Therapeutics' Share-based Compensation (Quarterly) stood at $3.9 million in 2021, then increased by 24.98% to $4.8 million in 2022, then tumbled by 73.70% to $1.3 million in 2023, then spiked by 125.91% to $2.9 million in 2024, then dropped by 4.79% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.1 million for Q2 2025, and $3.5 million during Q1 2025.